Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: A prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG)

Breast Cancer Research and Treatment

Volumn 119, Issue 1, 2010, Pages 169-176

  Tomova, Antoaneta ^a   Bartsch, Rupert ^b   Brodowicz, Thomas ^b   Tzekova, Valentina ^c   Timcheva, Constanta ^d   Wiltschke, Christoph ^b   Gerges, Dany Abi ^e   Pawlega, Jan ^f   Spanik, Stanislav ^g   Inbar, Moshe ^h   Zielinski, Christoph C ^b  

^a Plovdiv Cancer Centre   (Bulgaria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY HOSPITAL 'QUEEN GIOVANNA'   (Bulgaria)

^d National Oncology Center Bulgaria   (Bulgaria)

^e RIZK HOSPITAL   (Lebanon)

^f JAGIELLONIAN UNIVERSITY   (Poland)

^g Onkologicky Ustav sv Alzbety   (Slovakia)

^h TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Chemotherapy; Docetaxel; Gemcitabine; Metastatic breast cancer; Sequential versus concomitant

Indexed keywords

DOCETAXEL; GEMCITABINE; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EMBOLISM; ENTEROCOLITIS; EUROPE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL; NAUSEA; NEUTROPENIA; ONCOLOGY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TIME; VOMITING;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RECURRENCE; TAXOIDS; TIME FACTORS;

EID: 72449208461     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0553-4     Document Type: Article

References (28)

1. American Cancer Society Facts and Figs (2005) http://www.cancer.org. Accessed 1 July 2008
2. A Jemal R Siegel E Ward T Murray J Xu C Smigal MJ Thun 2006 Cancer statistics 2006 CA Cancer J Clin 56 106 130 10.3322/canjclin.56.2.106 16514137
3. IF Faneyte JL Peterse H Van Tinteren C Pronk M Bontenbal LV Beex E van der Wall DJ Richel MA Nooij EE Voest P Hupperets EM Ten Vergert EG de Vries S Rodenhuis MJ van de Vijver 2004 Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement Clin Cancer Res 10 4457 4463 10.1158/1078-0432.CCR-03-0054 1:CAS:528:DC%2BD2cXlsVWltbw%3D 15240537 (Pubitemid 38878889)
4. J O'Shaughnessy 2005 Extending survival with chemotherapy in metastatic breast cancer Oncologist 10 Suppl 3 S20 S29 10.1634/theoncologist.10-90003-20 (Pubitemid 43152727)
5. Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N (2009) Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev CD003372
6. ME Trudeau 1996 First-line treatment of metastatic breast cancer Anticancer Drugs 7 Suppl 2 S9 S12
7. S Chan K Friedrichs D Noel T Pintér S Van Belle D Vorobiof R Duarte M Gil Gil I Bodrogi E Murray L Yelle G von Minckwitz S Korec P Simmonds F Buzzi R González Mancha G Richardson E Walpole M Ronzoni M Murawsky M Alakl A Riva J Crown 1999 303 study group prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 study group J Clin Oncol 17 2341 2354 1:CAS:528:DyaK1MXltlylt70%3D 10561296
8. MJ Piccart-Gebhart T Burzykowski M Buyse G Sledge J Carmichael HJ Lück JR Mackey JM Nabholtz R Paridaens L Biganzoli J Jassem M Bontenbal J Bonneterre S Chan GA Basaran P Therasse 2008 Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer J Clin Oncol 26 1980 1986 10.1200/JCO.2007.10.8399 1:CAS:528: DC%2BD1cXlvFaqs7w%3D 18421049
9. R Fossati C Confalonieri V Torri E Ghislandi A Penna V Pistotti A Tinazzi A Liberati 1998 Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trias involving 31, 510 women J Clin Oncol 16 3439 3460 1:CAS:528:DyaK1cXmvFGrurs%3D 9779724
10. FJ Esteva V Valero L Pusztai L Boehnke-Michaud AU Buzdar GN Hortobagyi 2001 Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond Oncologist 6 133 146 10.1634/theoncologist.6-2-133 1:CAS:528: DC%2BD3MXktVarurw%3D 11306725 (Pubitemid 32323452)
11. PM Ravdin 1995 Docetaxel for the treatment of anthracycline-resistant breast cancer Semin Oncol 22 Suppl 4 S17 S21
12. T Brodowicz WJ Koestler S Tomek I Vaclavik V Herscovici C Wiltschke GG Steger CC Zielinski 2000 Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer Anti Cancer Drugs 11 149 153 10.1097/00001813-200003000-00002 1:CAS:528:DC%2BD3cXjtlKjsLc%3D 10831273 (Pubitemid 30258794)
13. J O'Shaughnessy D Miles S Vukelja V Moiseyenko JP Ayoub G Cervantes P Fumoleau S Jones WY Lui L Mauriac C Twelves G Van Hazel S Verma R Leonard 2002 Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results J Clin Oncol 20 2812 2823 10.1200/JCO.2002.09.002 12065558 (Pubitemid 34651510)
14. Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Lluch A, Schneeweiss A, Llombart A, Carrasco E, Fumoleau P (2005) Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel for anthrcycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Presented at the 41st ASCO annual meeting, Orlando, Fl, May 13-17, 2005. Accessed 30 August 2008. http://www.asco.org
15. JA O'Shaughnessy R Pluenneke J Sternberg P Khandelwal D Ilegbodu L Asmar 2006 Phase II trial of weekly docetaxel/gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer Clin Breast Cancer 6 505 510 10.3816/CBC.2006.n.003 16595033
16. CJA Van Moorsel GJ Peters HM Pinedo 2007 Gemcitabine: future prospects of single-agent and combination studies Oncologist 2 127 134
17. JF Bishop JP Matthews GA Young J Szer A Gillett D Joshua K Bradstock A Enno MM Wolf R Fox R Cobcroft R Herrmann M Van Der Weyden RM Lowenthal F Page OM Garson S Juneja 1996 A randomized study of high-dose cytarabine in induction therapy in acute myeloid leukaemia Blood 5 1710 1717
18. SB Kaye 1994 Gemcitabine: current status of phase I and II trials J Clin Oncol 12 1527 1531 1:STN:280:DyaK2czhsFeksw%3D%3D 8040662
19. V Heinemann LW Hertel GB Grindey W Plunkett 1988 Comparison of the cellular pharmacokinetics and toxicity of 2′, 2′- difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine Cancer Res 48 4024 4031 1:CAS:528:DyaL1cXlt1ajurc%3D 3383195
20. A Alexopoulos D Tryfonopoulos MV Karamouzis G Gerasimidis I Karydas K Kandilis J Stavrakakis H Stavrinides C Georganta A Ardavanis G Rigatos 2004 Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer Ann Oncol 15 95 99 10.1093/annonc/mdh028 1:STN:280:DC%2BD3srps1KmtA%3D%3D 14679126 (Pubitemid 38139609)
21. L Norton 1997 Evolving concepts in the systemic drug therapy of breast cancer Semin Oncol 24 Suppl 10 S3 S10
22. D Mavroudis N Malamos A Alexopoulos C Kourousis S Agelaki E Sarra A Potamianou C Kosmas G Rigatos T Giannakakis K Kalbakis F Apostolaki J Vlachonicolis S Kakolyris G Samonis V Georgoulias 1999 Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial Ann Oncol 10 211 215 10.1023/A:1008315723253 1:STN:280:DyaK1M7ptlKmsw%3D%3D 10093691 (Pubitemid 29113182)
23. D Miles G von Minckwitz AD Seidman 2007 Combination versus sequential single-agent therapy in metastatic breast cancer Oncologist 7 Suppl 6 S13 S19
24. GW Sledge D Neuberg P Bernardo JN Ingle S Martino EK Rowinsky WC Wood 2003 Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) J Clin Oncol 21 588 592 10.1200/JCO.2003.08. 013 12586793 (Pubitemid 46621890)
25. Koroleva I, Wojtukiewicz M, Zaluski J, Zaluski J, Arzumanov A, Biakhov M, Gad-El-Mawla N, Purkalne G, Blanc C (2001) Preliminary results of a phase II randomized trial of taxotere (T) and doxorubicin (A) give in combination or sequentially as first line chemotherapy (CT) for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 20:abstract #117
26. S Amat P Bougnoux F Penault-Llorca F Fétissof H Curé F Kwiatkowski JL Achard G Body J Dauplat P Chollet 2003 Neoadjuvant docetaxel for operable breast cancer induces a high pathological reponse and breast-conservation rate Br J Cancer 88 1339 1345 10.1038/sj.bjc.6600916 1:CAS:528:DC%2BD3sXktFOgu7c%3D 12778058 (Pubitemid 36606412)
27. G Fountzilas C Nicolaides D Bafaloukos A Kalogera-Fountzila H Kalofonos G Samelis G Aravantinos N Pavlidis 2000 Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study Cancer Invest 18 503 509 10.3109/07357900009012188 1:CAS:528:DC%2BD3cXls1Ogs74%3D 10923097
28. Brandi M, Giotta F, Vici P, Valerio MR, Vinciarelli G, Gebbia V, Galetta D, Lopez M, Colucci G (2001) Salvage chemotherapy with docetaxel (TXT) and gemcitabine (GEM) in metastatic breast cancer (MBC): preliminary results of a multicenter phase II trial of GOIM (Gruppo Oncologico dell'Italia Meridionale). Proc Am Soc Clin Oncol 20:abstract #1956